• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 疫苗与儿科住院。

COVID-19 vaccines versus pediatric hospitalization.

机构信息

Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China.

Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China.

出版信息

Cell Rep Med. 2023 Feb 21;4(2):100936. doi: 10.1016/j.xcrm.2023.100936. Epub 2023 Jan 23.

DOI:10.1016/j.xcrm.2023.100936
PMID:36801010
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9868379/
Abstract

Vaccine effectiveness of BNT162b2 and CoronaVac against COVID-19-associated hospitalization and moderate-to-severe disease due to SARS-CoV-2 Omicron BA.2 is studied from the 1.36 million doses administered to 766,601 of 953,400 children aged 3-11 years and adolescents aged 12-18 years in Hong Kong as of April 2022. These vaccines confer substantial protection.

摘要

研究了截至 2022 年 4 月在香港为 953400 名 3-11 岁儿童和 12-18 岁青少年中的 766601 人接种的 136 万剂 BNT162b2 和 CoronaVac 疫苗对 COVID-19 相关住院和因 SARS-CoV-2 奥密克戎 BA.2 导致的中重度疾病的有效性。这些疫苗提供了实质性的保护。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71e2/9975315/1429bed16008/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71e2/9975315/1429bed16008/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71e2/9975315/1429bed16008/fx1.jpg

相似文献

1
COVID-19 vaccines versus pediatric hospitalization.COVID-19 疫苗与儿科住院。
Cell Rep Med. 2023 Feb 21;4(2):100936. doi: 10.1016/j.xcrm.2023.100936. Epub 2023 Jan 23.
2
Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study.BNT162b2 和科兴疫苗预防奥密克戎变异株感染、住院和严重并发症的有效性：香港儿科人群的病例对照研究。
Emerg Microbes Infect. 2023 Dec;12(1):2185455. doi: 10.1080/22221751.2023.2185455.
3
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.BNT162b2 和科兴疫苗一剂、两剂和三剂对香港 COVID-19 的疫苗有效性：基于人群的观察性研究。
Lancet Infect Dis. 2022 Oct;22(10):1435-1443. doi: 10.1016/S1473-3099(22)00345-0. Epub 2022 Jul 15.
4
Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.随着时间的推移，科兴和国药疫苗对奥密克戎患者严重结局的疫苗有效性估计
JAMA Netw Open. 2023 Feb 1;6(2):e2254777. doi: 10.1001/jamanetworkopen.2022.54777.
5
Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study.60 岁及以上人群中接种 BNT162b2 和科兴疫苗对奥密克戎感染的有效性：病例对照研究。
J Travel Med. 2022 Dec 27;29(8). doi: 10.1093/jtm/taac119.
6
Effectiveness of CoronaVac and BNT162b2 Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.2 Infections in Hong Kong.科兴和国药疫苗对奥密克戎 BA.2 变异株引起的严重急性呼吸综合征冠状病毒 2 型感染的有效性：中国香港的一项回顾性队列研究。
J Infect Dis. 2022 Oct 17;226(8):1382-1384. doi: 10.1093/infdis/jiac360.
7
Effectiveness of mRNA and inactivated COVID-19 vaccines: A test-negative study in an infection-naïve Hong Kong population.mRNA 和灭活 COVID-19 疫苗的有效性：在无感染史的香港人群中进行的一项病例对照研究。
J Infect. 2023 Aug;87(2):136-143. doi: 10.1016/j.jinf.2023.05.020. Epub 2023 May 26.
8
Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong.BNT162b2和科兴疫苗在香港奥密克戎BA.2毒株流行期间对儿童和青少年预防新型冠状病毒感染的有效性
Commun Med (Lond). 2023 Jan 5;3(1):3. doi: 10.1038/s43856-022-00233-1.
9
Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.mRNA 疫苗（BNT162b2）和灭活 SARS-CoV-2 疫苗（CoronaVac）第二剂接种延迟对全因死亡率、急诊就诊和非计划性住院风险的影响。
BMC Med. 2022 Mar 17;20(1):119. doi: 10.1186/s12916-022-02321-4.
10
Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.疫苗加强针、疫苗类型以及混合免疫对合并症老年人中针对 SARS-CoV-2 原始株和奥密克戎变异株亚谱系 BA.2 和 BA.5 的体液和细胞免疫的影响：一项横断面研究。
EBioMedicine. 2023 Feb;88:104446. doi: 10.1016/j.ebiom.2023.104446. Epub 2023 Jan 25.

引用本文的文献

1
Outcomes of pediatric patients with suspected allergies to COVID-19 vaccines.疑似对新冠疫苗过敏的儿科患者的结局
J Allergy Clin Immunol Glob. 2024 Dec 17;4(1):100387. doi: 10.1016/j.jacig.2024.100387. eCollection 2025 Feb.
2
Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients.香港神经肌肉疾病患者接种三剂 BNT162b2 和科兴疫苗的中期免疫原性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2424615. doi: 10.1080/21645515.2024.2424615. Epub 2024 Nov 13.
3
Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac.

本文引用的文献

1
Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong.BNT162b2和科兴疫苗在香港奥密克戎BA.2毒株流行期间对儿童和青少年预防新型冠状病毒感染的有效性
Commun Med (Lond). 2023 Jan 5;3(1):3. doi: 10.1038/s43856-022-00233-1.
2
Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period.科兴疫苗在巴西奥密克戎流行期间对儿童 COVID-19 的疫苗效力。
Nat Commun. 2022 Aug 13;13(1):4756. doi: 10.1038/s41467-022-32524-5.
3
Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study.
使用BNT162b2进行加强免疫可改善接种科兴新冠疫苗的儿童人群的细胞免疫和体液免疫反应。
Vaccines (Basel). 2024 Aug 15;12(8):919. doi: 10.3390/vaccines12080919.
4
Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation.在 SARS-CoV-2 奥密克戎感染后，奈玛特韦/利托那韦在 12-17 岁儿童和青少年中的有效性：一项目标试验模拟。
Nat Commun. 2024 Jun 8;15(1):4917. doi: 10.1038/s41467-024-49235-8.
5
Transmission risks of Omicron BA.5 following inactivated COVID-19 vaccines among children and adolescents in China.中国儿童和青少年接种新冠灭活疫苗后感染奥密克戎BA.5的传播风险
Commun Med (Lond). 2024 May 18;4(1):92. doi: 10.1038/s43856-024-00521-y.
6
The effect of COVID-19 vaccine to the Omicron variant in children and adolescents: a systematic review and meta-analysis.新冠病毒疫苗对儿童和青少年奥密克戎变异株的影响：一项系统评价和荟萃分析。
Front Public Health. 2024 Apr 10;12:1338208. doi: 10.3389/fpubh.2024.1338208. eCollection 2024.
7
Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents.皮内与肌肉途径接种科兴疫苗在青少年中诱导的针对抗体和膜蛋白的特异性 T 细胞应答更强。
World J Pediatr. 2024 Apr;20(4):353-370. doi: 10.1007/s12519-023-00764-0. Epub 2023 Dec 12.
8
Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases.mRNA 疫苗和全病毒灭活疫苗在儿科神经肌肉疾病中的犹豫、反应原性和免疫原性。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2206278. doi: 10.1080/21645515.2023.2206278. Epub 2023 May 9.
BBIBP-CorV、BNT162b2和mRNA-1273疫苗在阿根廷奥密克戎疫情期间对儿童和青少年住院治疗的有效性：一项回顾性队列研究。
Lancet Reg Health Am. 2022 Sep;13:100316. doi: 10.1016/j.lana.2022.100316. Epub 2022 Jul 16.
4
Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age.BNT162b2 疫苗对 5 至 11 岁儿童中奥密克戎的有效性。
N Engl J Med. 2022 Aug 11;387(6):525-532. doi: 10.1056/NEJMoa2203209. Epub 2022 Jul 20.
5
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.意大利 2022 年 1 月至 4 月的一项回顾性分析：BNT162b2 疫苗在 5-11 岁儿童中预防 SARS-CoV-2 感染和 COVID-19 重症的效果。
Lancet. 2022 Jul 9;400(10346):97-103. doi: 10.1016/S0140-6736(22)01185-0. Epub 2022 Jul 1.
6
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age.BNT162b2 疫苗对 5 至 11 岁儿童中奥密克戎的有效性。
N Engl J Med. 2022 Jul 21;387(3):227-236. doi: 10.1056/NEJMoa2205011. Epub 2022 Jun 29.
7
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents.BNT162b2 疫苗和科兴疫苗在健康青少年中的免疫原性和反应原性。
Nat Commun. 2022 Jun 28;13(1):3700. doi: 10.1038/s41467-022-31485-z.
8
Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections.未接种疫苗住院儿童中严重急性呼吸综合征冠状病毒 2 型奥密克戎 BA.2 感染的严重程度：与流感和副流感感染的比较。
Emerg Microbes Infect. 2022 Dec;11(1):1742-1750. doi: 10.1080/22221751.2022.2093135.
9
Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile.科兴新冠疫苗在智利奥密克戎疫情期间对 3-5 岁儿童的有效性。
Nat Med. 2022 Jul;28(7):1377-1380. doi: 10.1038/s41591-022-01874-4. Epub 2022 May 23.
10
Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization.评估针对奥密克戎变异株引起的严重 COVID-19 疾病的疫苗有效性。世界卫生组织会议报告。
Vaccine. 2022 Jun 9;40(26):3516-3527. doi: 10.1016/j.vaccine.2022.04.069. Epub 2022 May 2.